Results 21 to 30 of about 750,934 (136)

PD-1 receptor blocker

open access: yesInternational journal of health sciences, 2022
PD-1 or the programmed cell death protein 1 plays a major role in eliciting the immune checkpoint response of T cells. They are the inhibitory receptors induced in activated T cells. The application of these receptors earns a great interest to investigate, in-depth, their mechanism of action and therapeutic success. The US FDA has successfully approved
Muhammad Faraz Shamshad   +6 more
openaire   +1 more source

PD-1 Blockers

open access: yesCell, 2015
Nivolumab and pembrolizumab are monoclonal antibodies that block the programmed death-1 receptor (PD-1, CD279), resulting in dis-inhibition of tumor-specific immune responses. Both are recently approved for use in the treatment of metastatic melanoma, and nivolumab as well for non-small cell lung cancer.
openaire   +2 more sources

A structural study of a C3H3 species coadsorbed with CO on Pd(1 1 1) [PDF]

open access: yes, 2008
The combination of chemical-state-specific C 1s scanned-energy mode photoelectron diffraction (PhD) and O K-edge near-edge X-ray absorption fine structure (NEXAFS) has been used to determine the local adsorption geometry of the coadsorbed C3H3 and CO ...
Allegretti, F.   +5 more
core   +1 more source

PD-1 Blockade in Chronically HIV-1-Infected Humanized Mice Suppresses Viral Loads [PDF]

open access: yes, 2013
An estimated 34 million people are living with HIV worldwide (UNAIDS, 2012), with the number of infected persons rising every year. Increases in HIV prevalence have resulted not only from new infections, but also from increases in the survival of HIV ...
Allen, Todd M.   +5 more
core   +6 more sources

The adsorption structure of furan on Pd(1 1 1) [PDF]

open access: yes, 2008
The structure of molecular furan, C4H4O, on Pd(1 1 1) has been investigated by O K-edge near-edge X-ray absorption fine structure (NEXAFS) and C 1s scanned-energy mode photoelectron diffraction (PhD).
Allegretti, F.   +5 more
core   +1 more source

Anti-PD-1

open access: yesCurrent Oncology Reports, 2022
Purpose of Review: Emerging data indicate that immune checkpoint blockade (ICB) in patients with metastatic melanoma can be stopped electively or at the time of toxicity with an acceptable risk for progression. However, the optimal treatment duration remains to be defined.
Jansen, Y   +3 more
openaire   +2 more sources

Coherent description of the intrinsic and extrinsic anomalous Hall effect in disordered alloys on an $ab$ $initio$ level [PDF]

open access: yes, 2010
A coherent description of the anomalous Hall effect (AHE) is presented that is applicable to pure as well as disordered alloy systems by treating all sources of the AHE on equal footing.
D. Ködderitzsch   +5 more
core   +2 more sources

m6A mRNA demethylase FTO regulates melanoma tumorigenicity and response to anti-PD-1 blockade [PDF]

open access: yes, 2019
Melanoma is one of the most deadly and therapy-resistant cancers. Here we show that N6-methyladenosine (m6A) mRNA demethylation by fat mass and obesity-associated protein (FTO) increases melanoma growth and decreases response to anti-PD-1 blockade ...
Aplin, Andrew E.   +10 more
core   +1 more source

TIGIT Marks Exhausted T Cells, Correlates with Disease Progression, and Serves as a Target for Immune Restoration in HIV and SIV Infection. [PDF]

open access: yes, 2016
HIV infection induces phenotypic and functional changes to CD8+ T cells defined by the coordinated upregulation of a series of negative checkpoint receptors that eventually result in T cell exhaustion and failure to control viral replication.
Abdel-Mohsen, Mohamed   +20 more
core   +3 more sources

Baseline T cell dysfunction by single cell network profiling in metastatic breast cancer patients. [PDF]

open access: yes, 2019
BackgroundWe previously reported the results of a multicentric prospective randomized trial of chemo-refractory metastatic breast cancer patients testing the efficacy of two doses of TGFβ blockade during radiotherapy.
Demaria, Sandra   +10 more
core   +1 more source

Home - About - Disclaimer - Privacy